Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies

AAPS Journal

Volumn 15, Issue 3, 2013, Pages 797-807

  Parra Guillen, Zinnia P ^a   Berraondo, Pedro ^b   Grenier, Emmanuel ^c   Ribba, Benjamin ^d   Troconiz, Iñaki F ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITÉ DE LYON   (France)

^d INRIA RHÔNE ALPES   (France)

Author keywords

cancer vaccine and mice; immunotherapy; mathematical modelling; population approach

Indexed keywords

CANCER VACCINE; CYAA E7 VACCINE; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CELL DEATH; COMPUTER ANALYSIS; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; EXPLORATORY RESEARCH; FEMALE; HYDRODYNAMICS; IMMUNE RESPONSE; IMMUNOSTIMULATION; MATHEMATICAL MODEL; MOUSE; NONHUMAN; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; SOLID TUMOR; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CANCER VACCINES; CYTOKINES; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879795123     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9483-5     Document Type: Article

References (50)

1. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83-117.
2. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265-77.
3. Melief CJM. Cancer immunotherapy by dendritic cells. Immunity. 2008;29:372-83.
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
5. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162-79.
6. Schreiber. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565.
7. Préville X, Ladant D, Timmerman B, Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res. 2005;65:641-9.
8. Berraondo P, Nouzé C, Préville X, Ladant D, Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res. 2007;67:8847-55.
9. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11:805-12.
10. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-15.
11. Alpizar YA, Chain B, Collins MK, Greenwood J, Katz D, Stauss HJ, et al. Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol Immunother. 2011;60:1127-35.
12. Agur Z, Vuk-Pavlovic S. Mathematical modeling in immunotherapy of cancer: personalizing clinical trials. Mol Ther. 2012;20:1-2.
13. Kirschner D, Panetta JC. Modeling immunotherapy of the tumor-immune interaction. J Math Biol. 1998;37:235-52.
14. De Pillis L, Radunskaya A. A mathematical tumor model with immune resistance and drug therapy: an optimal control approach. J Ther Med. 2001;3:79-100.
15. de Pillis LG, Radunskaya AE, Wiseman CL. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 2005;65:7950-8.
16. Cappuccio A, Elishmereni M, Agur Z. Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res. 2006;66:7293-300.
17. Kronik N, Kogan Y, Vainstein V, Agur Z. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother. 2008;57:425-39.
18. Joshi B, Wang X, Banerjee S, Tian H, Matzavinos A, Chaplain MAJ. On immunotherapies and cancer vaccination protocols: a mathematical modelling approach. J Theor Biol. 2009;259:820-7.
19. Kronik N, Kogan Y, Elishmereni M, Halevi-Tobias K, Vuk-Pavlović S, Agur Z. Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models. PLoS One. 2010;5:e15482.
20. Eftimie R, Bramson J, Earn DJD. Interactions between the immune system and cancer: a brief review of non-spatial mathematical models. Bull Math Biol. 2011;73:2-32.
21. Pappalardo F, Forero IM, Pennisi M, Palazon A, Melero I, Motta S. SimB16: modeling induced immune system response against B16-melanoma. PLoS One. 2011;6:e26523.
22. Elishmereni M, Kheifetz Y, Søndergaard H, Overgaard R, Agur Z. An integrated disease/pharmacokinetic/pharmacodynamic model suggests improved interleukin-21 regimens validated prospectively for mouse solid cancers. PLoS Comput Biol. 2011;7:e1002206-6.
23. Kogan Y, Halevi-Tobias K, Elishmereni M, Vuk-Pavlović S, Agur Z. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization. Cancer Res. 2012;72:2218-27.
24. Tan S, Cavanagh L, d'Advigor W, Shackel N, Fazekas de St Groth B, Weninger W. Phenotype and functions of conventional dendritic cells are not compromised in aged mice. Immunol Cell Biol. 2012;90:722-32.
25. Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol. 2011;186:807-15.
26. Beal S, Sheiner L, Boeckmann A. NONMEM Users Guide. Icon Development Solutions. 1989-2006.
27. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481-504.
28. Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241-57.
29. Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Pharmacodyn. 1994;22:431-45.
30. Jacqmin P, Snoeck E, Van Schaick E, Gieschke R, Pillai P, Steimer JL, et al. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn. 2007;34:57-85.
31. Carlsson KC, Savi RM, Hooker AC, Karlsson MO. Modeling subpopulations with the $ MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making. AAPS J. 2009;11:148-54.
32. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988;48:7067-71.
33. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 2004;64:1094-101.
34. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34:711-26.
35. Norton L, Simon R, Brereton HD, Bogden AE. Predicting the course of Gompertzian growth. Nature. 1976;264:542-5.
36. Terranova N, Magni P. TGI-Simulator: a visual tool to support the preclinical phase of the drug discovery process by assessing in silico the effect of an anticancer drug. Comput Methods Programs Biomed. 2012;105:162-74.
37. Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice. Eur J Cancer. 2008;44:142-50.
38. Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW, et al. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos. 2010;38:1436-42.
39. Ribba B, Watkin E, Tod M, Girard P, Grenier E, You B, et al. A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. Eur J Cancer. 2011;47:479-90.
40. Kuznetsov VA, Knott GD. Modeling tumor regrowth and immunotherapy. Math Comput Model. 2001;33:1275-87.
41. Romero E, de Mendizabal NV, Cendrós JM, Peraire C, Bascompta E, Obach R, et al. Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. J Pharmacol Exp Ther. 2012;342:788-98.
42. Salman S, Sy SKB, Ilett KF, Page-Sharp M, Paech MJ. Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk. Eur J Clin Pharmacol. 2011;67:899-908.
43. Hayes S, Ouellet D, Zhang J, Wire MB, Gibiansky E. Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. J Clin Pharmacol. 2011;51:1403-17.
44. Dobrzanski M, Rewers Felkins K, Samad K, Quinlin I, Phillips C, Robinson W, et al. Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunol Immunother. 2012;61:839-54.
45. Sakakibara M, Kanto T, Hayakawa M, Kuroda S, Miyatake H, Itose I, et al. Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. Cancer Immunol Immunother. 2011;60:1565-75.
46. Snoeck E, Chanu P, Lavielle M, Jacqmin P, Jonsson EN, Jorga K, et al. A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther. 2010;87:706-13.
47. Lu JF, Claret L, Sutjandra L, Kuchimanchi M, Melara R, Bruno R, et al. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. Cancer Chemother Pharmacol. 2010;66:1151-8.
48. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127:759-67.
49. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23:viii6-9.
50. Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, et al. Improving the efficacy of cancer immunotherapy. Eur J Cancer. 2009;45:1424-31.